Translational Approach to Predicting the Efficacy of Maraviroc-Based Regimens as HIV Preexposure Prophylaxis
Copyright © 2020 American Society for Microbiology..
Maraviroc-based regimens have been explored as preexposure prophylaxis (PrEP) against human immunodeficiency virus (HIV). In this study, we utilized mucosal tissue drug exposure data, combined with target concentrations generated in vitro, in a pharmacokinetic-pharmacodynamic analysis to predict the effects of drug combinations and adherence on PrEP efficacy. Mucosal tissue concentrations of maraviroc were measured in 24 healthy women. The 90% effective concentrations (EC90) of maraviroc (alone and combined with tenofovir and emtricitabine) for protection against HIV were identified in CD4+ T cells. Monte Carlo simulations were performed to identify dosing strategies to protect colorectal and female genital tract (FGT) tissues from HIV infection. Colorectal maraviroc concentrations were 350-fold higher than in the FGT. Under steady-state conditions, our model predicted that one 300-mg dose/week was sufficient to protect colorectal tissue from HIV in 99% of the population, while 300 mg daily would protect the FGT in only 63% of the population. FGT protection increased to >90% when maraviroc was used in combination with tenofovir (5 doses/week) or emtricitabine (3 doses/week). Poor adherence resulted in a drastic decrease in efficacy in the FGT but not colorectal tissue. However, greater forgiveness was seen when maraviroc was combined with tenofovir or emtricitabine, suggesting that maraviroc should not be used alone as PrEP.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:64 |
|---|---|
| Enthalten in: |
Antimicrobial agents and chemotherapy - 64(2020), 2 vom: 27. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Srinivas, Nithya [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.01.2021 Date Revised 04.01.2021 published: Electronic-Print Citation Status MEDLINE |
|---|
| doi: |
10.1128/AAC.01729-19 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM303436654 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM303436654 | ||
| 003 | DE-627 | ||
| 005 | 20231225112826.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/AAC.01729-19 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1011.xml |
| 035 | |a (DE-627)NLM303436654 | ||
| 035 | |a (NLM)31740561 | ||
| 035 | |a (PII)e01729-19 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Srinivas, Nithya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Translational Approach to Predicting the Efficacy of Maraviroc-Based Regimens as HIV Preexposure Prophylaxis |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.01.2021 | ||
| 500 | |a Date Revised 04.01.2021 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 American Society for Microbiology. | ||
| 520 | |a Maraviroc-based regimens have been explored as preexposure prophylaxis (PrEP) against human immunodeficiency virus (HIV). In this study, we utilized mucosal tissue drug exposure data, combined with target concentrations generated in vitro, in a pharmacokinetic-pharmacodynamic analysis to predict the effects of drug combinations and adherence on PrEP efficacy. Mucosal tissue concentrations of maraviroc were measured in 24 healthy women. The 90% effective concentrations (EC90) of maraviroc (alone and combined with tenofovir and emtricitabine) for protection against HIV were identified in CD4+ T cells. Monte Carlo simulations were performed to identify dosing strategies to protect colorectal and female genital tract (FGT) tissues from HIV infection. Colorectal maraviroc concentrations were 350-fold higher than in the FGT. Under steady-state conditions, our model predicted that one 300-mg dose/week was sufficient to protect colorectal tissue from HIV in 99% of the population, while 300 mg daily would protect the FGT in only 63% of the population. FGT protection increased to >90% when maraviroc was used in combination with tenofovir (5 doses/week) or emtricitabine (3 doses/week). Poor adherence resulted in a drastic decrease in efficacy in the FGT but not colorectal tissue. However, greater forgiveness was seen when maraviroc was combined with tenofovir or emtricitabine, suggesting that maraviroc should not be used alone as PrEP | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a antiretroviral | |
| 650 | 4 | |a dose response | |
| 650 | 4 | |a emtricitabine | |
| 650 | 4 | |a maraviroc | |
| 650 | 4 | |a population pharmacokinetics-pharmacodynamics | |
| 650 | 4 | |a preexposure prophylaxis | |
| 650 | 4 | |a quantitative pharmacology | |
| 650 | 4 | |a tenofovir | |
| 650 | 4 | |a translational medicine | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Tenofovir |2 NLM | |
| 650 | 7 | |a 99YXE507IL |2 NLM | |
| 650 | 7 | |a Emtricitabine |2 NLM | |
| 650 | 7 | |a G70B4ETF4S |2 NLM | |
| 650 | 7 | |a Maraviroc |2 NLM | |
| 650 | 7 | |a MD6P741W8A |2 NLM | |
| 700 | 1 | |a Cottrell, Mackenzie |e verfasserin |4 aut | |
| 700 | 1 | |a Maffuid, Kaitlyn |e verfasserin |4 aut | |
| 700 | 1 | |a Prince, Heather A |e verfasserin |4 aut | |
| 700 | 1 | |a Nelson, Julie A E |e verfasserin |4 aut | |
| 700 | 1 | |a White, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Sykes, Craig |e verfasserin |4 aut | |
| 700 | 1 | |a Dellon, Evan S |e verfasserin |4 aut | |
| 700 | 1 | |a Madanick, Ryan D |e verfasserin |4 aut | |
| 700 | 1 | |a Shaheen, Nicholas J |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzalez, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Kashuba, Angela D M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antimicrobial agents and chemotherapy |d 1972 |g 64(2020), 2 vom: 27. Jan. |w (DE-627)NLM000026506 |x 1098-6596 |7 nnns |
| 773 | 1 | 8 | |g volume:64 |g year:2020 |g number:2 |g day:27 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/AAC.01729-19 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 64 |j 2020 |e 2 |b 27 |c 01 | ||